NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand - Endpoints News

NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand - Endpoints News
Health

Listen to this article

0%

Af­ter tin­ker­ing with the bi­ol­o­gy of the broad­ly ap­peal­ing an­ti-in­flam­ma­to­ry NL­RP3 path­way, NodThera is now plot­ting its piv­otal tri­al plans for 2027.

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected